A study validating Natera’s methylation‑based Latitude tissue‑free MRD assay found postsurgical ctDNA positivity linked to markedly worse disease‑free survival and a median lead time of roughly 4.6 months to clinical relapse, supporting its prognostic value in colorectal cancer. The company highlighted high specificity in patients not receiving adjuvant chemo and strong longitudinal relapse detection performance. Separately Natera submitted a premarket approval application to the FDA for its Signatera MRD assay as a companion diagnostic for muscle‑invasive bladder cancer, citing IMvigor011 trial data showing Signatera‑guided treatment improved disease‑free and overall survival. Together the moves push Natera’s ctDNA tools closer to both clinical adoption and regulatory clearance.